Day: January 25, 2024

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

Written by Customer Service on January 25, 2024. Posted in Public Companies.

Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for which Dupixent is approved in children this young, underscoring the commitment to bringing therapies to young patients with significant unmet needs EoE is one of five FDA-approved indications for Dupixent in the U.S. for which type 2 inflammation is an underlying driver TARRYTOWN, N.Y. and PARIS, Jan. 25, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE). Dupixent is now the first and only...

Record date for the transfer of warrants to existing shareholders is set to 2 February 2024

Written by Customer Service on January 25, 2024. Posted in Public Companies.

As announced on 12 January 2024, the board of directors of Terranet AB (“Terranet” or the “Company”) has resolved to transfer warrants of series TO8 without consideration to the Company’s existing shareholders. The record date for receiving the warrants of series TO8 has now been set to 2 February 2024. The exercise period for subscription of shares with the support of warrants of series TO8 runs from 18 November 2024 to 29 November 2024. As announced through a press release on 12 January 2024, the board of directors of Terranet has resolved on two directed issues of units, one of which is conditional upon approval by the extraordinary general meeting on 31 January 2024. In order to give existing shareholders in the Company the opportunity to compensate themselves to some extent for the dilution effect that...

Christian Dior: 2023 : New record year for Christian Dior group

Written by Customer Service on January 25, 2024. Posted in Earnings Releases And Operating Results.

2023: New record year for Christian Dior group . Revenue: €86.2 billion. Profit from recurring operations: €22.8 billion. Growth higher in the fourth quarter than in the third quarter. Major economic and social impact in France and around the world Paris, January 25th, 2024 Christian Dior group recorded revenue of €86.2 billion in 2023, equating to organic growth of 13% with respect to 2022. All business groups reported strong organic revenue growth, with the exception of Wines & Spirits, which was faced with a high basis of comparison and high inventory levels. Europe, Japan and the rest of Asia achieved double-digit organic growth. In the fourth quarter, organic revenue growth came to 10%. Profit from recurring operations stood at €22.8 billion for 2023, up 8%. The current operating margin remained stable with respect to 2022. Group...

Plata Wine Partners Expands Portfolio of Exclusive Retail Wine Brands

Written by Customer Service on January 25, 2024. Posted in Mergers And Acquisitions.

Acquisition of 14 brands from Purple Brands enhances collection of wines from premium California appellations Napa, CA, Jan. 25, 2024 (GLOBE NEWSWIRE) — Plata Wine Partners officially announced the purchase of Purple Brands’ portfolio of exclusive retail wines. The acquisition includes 14 brands, such as Donovan-Parke, Main & Geary, Athenaeum, and Shiloh Road, highlighting fruit from distinctive California growing regions. “Bringing these new brands into our fold pushes us closer to producing 500,000 cases of wine this year. These lines also beautifully complement our current collection of premium wines from California appellations, including sub-AVAs in Napa, Sonoma, Monterey, San Luis Obispo, and Santa Barbara counties,” said Scott Smith, President and CEO, Plata Wine Partners. “It’s an exciting time of growth and new opportunities.” Plata...

Airport Passenger Screening Systems Market Size Worth USD 5.69 Billion in 2032 | Emergen Research

Written by Customer Service on January 25, 2024. Posted in Mergers And Acquisitions.

Rising number of terrorist attacks globally is creating a high demand for implementation of passenger screening systems that can handle higher passenger volumes without compromising security which is a major factor driving the Airport Passenger Screening Systems market revenue growth. Vancouver, Jan. 25, 2024 (GLOBE NEWSWIRE) — The global airport passenger screening systems market size was USD 2.35 Billion in 2022 and is expected to register a revenue CAGR of 9.3% during the forecast period. Rising number of terrorist attacks globally is creating a high demand for implementation of passenger screening systems that can handle higher passenger volumes without compromising security which is a major factor driving the market revenue growth. As more people prefer to fly for business and vacations, airports are improving their security...

Renovaro Biosciences Announces Results of Special Meeting of Shareholders

Written by Customer Service on January 25, 2024. Posted in Public Companies.

LOS ANGELES, Jan. 25, 2024 (GLOBE NEWSWIRE) — Renovaro Biosciences Inc. (NASDAQ: RENB) (the “Company”), a biotechnology corporation focusing on cell, gene, and immunotherapy, announced today the results of the Company’s Special Meeting of Shareholders held at 12:00 pm ET on January 25, 2024. All of the matters put forward before the Company’s shareholders for consideration and approval, as set out in the Company’s definitive proxy statement dated January 3, 2024, were approved by the requisite number of votes cast at the meeting. For complete results on all matters voted on at the meeting, please consult the Company’s Form 8-K which will be filed on EDGAR at www.sec.gov/edgar. ABOUT THE COMPANYRenovaro has developed advanced cell, gene, and immunotherapy platforms designed to renew the body’s natural tumor-fighting...

Toll Brothers Announces Opening of Brookview Single-Family Home Community in Lake Stevens, Washington

Written by Customer Service on January 25, 2024. Posted in Public Companies.

Onsite model home grand opening event to be held on Saturday, January 27 from noon – 4pm PTBrookview by Toll BrothersBrookview by Toll Brothers is now open in Lake Stevens, Washington; a new model home and quick move-in homes are available for tours.Brookview by Toll Brothers“Brookview is a unique community that offers a variety of flexible living options and an array of personalization selections,” said Kelley Moldstad, Group President of Toll Brothers in Washington and Oregon.LAKE STEVENS, Wash., Jan. 25, 2024 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the grand opening of its new Brookview community in Lake Stevens, Washington. The new boutique community of 23 homes, which is now open for sale, offers a collection of 2- and 3-story home...

OHA is the Lead Left Arranger of Greenway Health’s Private Unitranche Financing

Written by Customer Service on January 25, 2024. Posted in Public Companies.

New York, New York, Jan. 25, 2024 (GLOBE NEWSWIRE) — Oak Hill Advisors (“OHA”) served as the Lead Left Arranger of a private unitranche financing for Greenway Health, a provider of electronic health record and practice management solutions to the U.S. ambulatory market. OHA committed to half of the $375 million term loan used to refinance the company’s maturing syndicated first lien debt. OHA’s industry-specialist investment team model positioned it to quickly and confidently diligence the opportunity, with its speed being a meaningful factor in closing the transaction. OHA is one of the earliest investors in software credit, having deployed over $30 billion in both liquid and private financings for over 130 portfolio companies since 2004, and maintains a distinctive understanding of healthcare information technology through its...

Commissioning of Logelbach solar power plant

Written by Customer Service on January 25, 2024. Posted in Public Companies.

Commissioning of Logelbach solar power plant Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, announces the start of production of its Logelbach solar power plant in the Grand-Est region of France with a capacity of 12.1 megawatts Logelbach solar power plant is located in the town of Wintzenheim, on the outskirts to the west of Colmar in the Collectivité Européenne d’Alsace. Built on the former Ligibel landfill site, it now offers a sustainable solution for the renewable energy production by making economic and environmental use of this degaged site. With a capacity of 12.1 megawatts, the Logelbach solar farm covers 12 hectares and has 21,384 solar panels. Annual production is equivalent to the electricity consumption of around 6,000 people. By contributing to France’s energy...

PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada

Written by Customer Service on January 25, 2024. Posted in Public Companies.

License allows PharmAla to drive revenue and growth while remaining true to its “regulatory first” mission VANCOUVER, British Columbia, Jan. 25, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has been granted a Controlled Drugs & Substances Dealer’s License (CDSL) by Health Canada, Canada’s federal health regulator. The CDSL allows PharmAla to offer for sale both 3,4 Methylenedioxymethamphetamine (MDMA) and Psilocybin to those authorized to legally hold these materials. “PharmAla is breaking new ground in the Canadian market. MDMA-Assisted Therapy is still very new – with PharmAla’s...

Day: January 25, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice